Ascendiant Capital Markets Lowers AIM ImmunoTech (NYSEAMERICAN:AIM) Price Target to $7.00

AIM ImmunoTech (NYSEAMERICAN:AIM) had its price target lowered by analysts at Ascendiant Capital Markets from $9.00 to $7.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock.

AIM ImmunoTech Price Performance

Shares of NYSEAMERICAN AIM opened at $0.24 on Thursday. AIM ImmunoTech has a 1-year low of $0.19 and a 1-year high of $2.98. The business’s fifty day moving average price is $0.29 and its two-hundred day moving average price is $0.54. The firm has a market capitalization of $7.25 million, a PE ratio of -0.08 and a beta of 1.20.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.43) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter. Equities research analysts expect that AIM ImmunoTech will post -0.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in AIM ImmunoTech stock. DRW Securities LLC grew its holdings in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) by 60.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,545 shares of the company’s stock after buying an additional 26,254 shares during the period. DRW Securities LLC owned 2.12% of AIM ImmunoTech worth $79,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.